Litcius/Paper detail

Novel CRBN-Recruiting Proteolysis-Targeting Chimeras as Degraders of Stimulator of Interferon Genes with In Vivo Anti-Inflammatory Efficacy

Jin Liu, L. Yuan, Yong Ruan, Bulian Deng, Zicao Yang, Yichang Ren, Ling Li, Ting Liu, Huiting Zhao, Ruiyao Mai, Jianjun Chen

2022Journal of Medicinal Chemistry96 citationsDOIOpen Access PDF

Abstract

The activation of the cyclic GMP-AMP synthase-stimulator of interferon gene (STING) pathway has been associated with the pathogenesis of many autoimmune and inflammatory disorders, and small molecules targeting STING have emerged as a new therapeutic strategy for the treatment of these diseases. While several STING inhibitors have been identified with potent anti-inflammatory effects, we would like to explore STING degraders based on the proteolysis-targeting chimera (PROTAC) technology as an alternative strategy to target the STING pathway. Thus, we designed and synthesized a series of STING protein degraders based on a small-molecule STING inhibitor (C-170) and pomalidomide (a CRBN ligand). These compounds demonstrated moderate STING-degrading activities. Among them, SP23 achieved the highest degradation potency with a DC50 of 3.2 μM. Importantly, SP23 exerted high anti-inflammatory efficacy in a cisplatin-induced acute kidney injury mouse model by modulating the STING signaling pathway. Taken together, SP23 represents the first PROTAC degrader of STING deserving further investigation as a new anti-inflammatory agent.

Topics & Concepts

StingStimulator of interferon genesChemistryProteolysisIn vivoInterferonPharmacologyReceptorImmunologyMedicineBiologyInnate immune systemBiochemistryAerospace engineeringEnzymeBiotechnologyEngineeringinterferon and immune responsesProtein Degradation and InhibitorsUbiquitin and proteasome pathways